To evaluate treatment patterns, molecular responses, treatment-free remission (TFR), and safety among Omani patients with chronic-phase CML treated with TKIs.
Approach:
Study Design: Retrospective single-center study conducted at Sultan Qaboos University Hospital, including adult patients with chronic-phase CML treated with TKIs from January 2008 to September 2024.
Data Collection: Demographics, Sokal risk, treatment lines, molecular responses, TFR, and adverse drug reactions (ADRs) were analyzed.
Key Findings:
Among12pties4375yrhdlwkbf8cvju960
Interpretation:
First-line imatinib provided slower and less frequent molecular responses compared to second-generation TKIs.
Limitations:
Small patient numbers limit the interpretation of TFR rates.
Single-center study may not represent broader populations.
Conclusion:
Findings support a response-guided, risk-adapted approach to TKI selection.
